I recently did a poll on people’s reactions to the new paper reporting use an all-chemical approach to making iPS cells through cellular reprogramming. I got a good number of responses relatively quickly. The results so far suggest that by far most people think it is too soon to know the importance of this new report. However, of those willing to voice a more clear cut opinion at this early stage, far more were leaning towards the positive. In fact, the 2nd most common …Read More
How important is the new development of all chemical reprogramming to make iPS cells? The group led by Hongkui Deng at Peking University in Beijing reported in Science that they used 7 chemicals to make what appear to be mouse iPS cells. I’m hearing a wide range of opinions directly from people in the know. What’s your take on the impact of this finding? Please take our poll.
In a rare sign of stem cell international regulatory unity, the Japanese Health Ministry (厚生労働省) and the US FDA have agreed to develop a joint, unified regulatory framework for clinical studies of human iPS cells for use in treating retinal diseases. Presumably the rules would also guide clinical use of iPS cells to treat other diseases. The two regulatory bodies aim to have the joint rules in place by 2015. To me this seems like a positive development, but it may come a bit …Read More
New ISSCR President, Dr. Janet Rossant, kindly agreed to do an interview with me focused on the future of ISSCR, her plans for her tenure, and some key issues in the field. Dr. Rossant is Chief of Research at The Hospital for Sick Children in Toronto. 1. The stem cell arena is a very rapidly changing one on many levels. As President how do you see ISSCR changing and evolving in the coming year to effectively deal with critical emerging issues? Rossant: Stem cell research is indeed …Read More